Related Experiment Videos
[Hypercholesterolemia and hypertension--equivalent risk factors?]
1Spezialarzt für Innere Medizin FMH, Arztehaus Sonnenhof, Zürich.
Insights
This study questions the premise of hypercholesterolaemia management, finding blood pressure interventions more beneficial than cholesterol-lowering measures. It suggests limiting medical supervision for the general population and focusing on nutritional changes.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Medical Economics
Context:
- Current hypercholesterolaemia guidelines rely on serum cholesterol levels in healthy populations.
- Hypertension trials often treat controls with standard care, unlike lipid trials.
- High-risk groups show a greater benefit from blood pressure management than cholesterol reduction.
Purpose:
- To compare observational and interventional trials for hypertension and hypercholesterolaemia.
- To evaluate the comparative effectiveness of treatments for these two risk factors.
- To re-evaluate current medical screening and intervention strategies.
Summary:
- Hypertension management yields significantly higher benefits than cholesterol-lowering measures, especially in high-risk individuals.
- The study highlights disparities in control group treatment between hypertension and lipid trials.
- Familial hypercholesterolaemia shows poorer treatment outcomes compared to malignant hypertension.
Impact:
- Recommends a critical analysis of medical screening and intervention protocols.
- Advocates for reduced medical supervision for the general population.
- Suggests prioritizing nutritional advice over widespread drug treatment for hypercholesterolaemia in healthy individuals.
Abstract:
Official recommendations for handling of hypercholesterolaemia are based on the comprehensive knowledge of serum cholesterol values in the healthy population as knowledge of blood pressure is desirable. To question this premise, both observational and interventional trials concerning the two risk factors are compared. Apparent similarities are produced by the fact that in hypertension trials control persons often are treated in the condition of normal care, whereas in lipid trials they are not. Early hypertension studies confirm beyond any doubt that the profit of hypotensive drugs is much higher than that of any cholesterol-lowering measure. The difference is most striking in the high-risk groups, comparing the treatment benefit in malignant hypertension with the hitherto poor results in familial hypercholesterolaemia. The author suggests a thorough analysis of all screening tests and interventional recommendations in medicine, aiming to allocate only a limited proportion of the normal population to regular medical supervision. There hypercholesterolaemia will have its modest place. Instead of intensified screening and drug treatment of healthy individuals, general advice for nutritional changes seems more reasonable.